Study of Eltrombopag in Platelet Refractory Thrombocytopenia

• Status: Withdrawn
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This phase II trial is studying the effects of the drug eltrombopag has on thrombocytopenia (low platelet count). Eltrombopag is approved by the FDA for the treatment of thrombocytopenia (low platelet count) in adults who have had an insufficient response to medications such as corticosteroids and immunoglobulins. Eltrombopag is not approved by the FDA (Food and Drug Administration) for the treatment of thrombocytopenia refractory to platelet transfusion and so for this study is considered investigational.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Cincinnati
• Collaborator: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Laboratory diagnosis of platelet refractoriness

• Diagnosis of platelet dependence

• Adequate liver and renal laboratory screening tests

Exclusion Criteria:

• Patients with thrombocytopenia that are responsive to platelet therapy

• Patients actively receiving intravenous immunoglobulin, plasmapheresis or cytotoxic medications for thrombocytopenia